Supply-route comparison · C-030
Grey-market versus prescribed GLP-1 products
The molecule name is only one attribute. A regulated medicine and a product sold through an unregulated website can share a label while differing on identity, quantity, sterility, storage, clinical oversight and recourse.
A prescribed GLP-1 medicine reaches a patient through an authorised product, a registered pharmacy and clinical assessment. A grey-market vial or pen does not carry those assurances. Trial evidence for semaglutide or tirzepatide cannot establish the contents, dose accuracy, sterility or storage history of a separate product bought online.
Pain that may spread to the back, with or without nausea or vomiting, can be a sign of acute pancreatitis. Seek urgent medical help through NHS 111, A&E or 999 as the situation requires. Do not delay care while trying to identify a product.
Two routes that share very little
The comparison below concerns product assurance and accountability. It does not claim that an authorised medicine is risk-free, or that a grey-market product contains the substance named on its label.
| Attribute | Prescribed authorised medicine | Grey-market vial or pen | Decision consequence |
|---|---|---|---|
| Identity | Active substance and finished product are controlled under a marketing authorisation. | A label or seller claim is not proof of identity. The product may be substituted, diluted or counterfeit. | The trial literature cannot identify an untested item. |
| Quantity | Strength, presentation, manufacturing controls and batch release are defined. | Stated quantity may lack a traceable, independent quantitative result linked to the item. | A purity percentage does not establish amount in a vial. |
| Sterility and endotoxin | Parenteral manufacture sits within regulated quality controls and batch release. | A seller document may omit these attributes or refer to another sample. | Identity and purity tests do not answer microbiological questions. |
| Storage and transport | The licensed supply chain sets labelled conditions and accountable handling. | Temperature excursions, relabelling and repacking may be undocumented. | A genuine substance can still become an unsuitable product. |
| Clinical oversight | A prescriber checks indication, contraindications, interactions and follow-up needs. | Social-media or web sales may bypass assessment and monitoring. | Product risk and patient-specific risk can compound. |
| Adverse-event route | Patient, prescriber, pharmacist and manufacturer can feed safety monitoring. | The seller may not have a pharmacovigilance system or reliable contact route. | Report suspected medicine problems through the MHRA Yellow Card scheme. |
| Legal recourse | Registered professionals, regulated premises and an identifiable marketing-authorisation holder create accountability. | Operators may conceal jurisdiction, identity or payment trail. | Recovery, recall and investigation can be harder. |
What evidence transfers, and what does not
Do authorised semaglutide medicines have relevant human evidence?
Yes, for specific authorised products, populations, indications and outcomes. The evidence applies alongside the product information, eligibility rules and safety monitoring used in those studies and approvals. Read the semaglutide evidence and product-route distinction.
Do authorised tirzepatide medicines have relevant human evidence?
Yes, for specific authorised presentations and uses. That evidence does not verify a vial or pen obtained outside the regulated route. Read the tirzepatide evidence and counterfeit context.
Does retatrutide trial evidence validate an online product?
No. Retatrutide has human trial evidence, but it is not an authorised medicine in the UK. A study result does not establish what an online seller supplied. See the retatrutide trial and UK-status record.
Can a seller label establish clinical equivalence?
No reliable basis exists for treating the name on an unverified product as evidence of equivalence to an authorised medicine. Identity, strength, formulation, impurities, sterility and stability would all need appropriate evidence.
Research record added 6 September 2026. Two new records follow these separate evidence routes: the GLP-1 laboratory impurity study and the retatrutide medical-record preprint. Read each record with its study-design and product-identity limits.
The UK position in plain terms
Semaglutide, tirzepatide and liraglutide weight-management medicines are prescription-only. The MHRA says they should be obtained only after a clinical consultation and supplied by a registered pharmacy. Powder in vials that needs mixing is not an authorised presentation for these medicines in the UK.
In July 2026, the MHRA warned that retatrutide was not authorised in the UK and that products sold online under that name had not been assessed for safety, quality or effectiveness. The regulator also says there is no guarantee that such products contain retatrutide.
Check a pharmacy on the General Pharmaceutical Council register. An offer to supply a prescription-only medicine without a prescription is a warning sign. Read why these products cannot be lawfully supplied through an ordinary grey-market route.
What can be checked at all?
A laboratory can address individual attributes when the method, sample and reporting are suitable. Mass spectrometry may support identity. A validated assay may support quantity. Separate methods are needed for sterility, endotoxin and named contaminants.
The result still belongs to the tested sample. It does not automatically apply to every unit sold under the same name. Start with which product attributes can be verified at all, then ask whether the sample can be linked to the item in question.
Source ledger
Primary regulatory and product sources checked on 7 August 2026.
- MHRA: No summer shortcut for safe weight loss · UK prescription route, retatrutide status and online-product warning, 24 July 2026.
- MHRA patient guidance on GLP-1 medicines · authorised presentations, counterfeits and urgent symptoms, updated 5 February 2026.
- MHRA Products · current UK product information search.
- MHRA Yellow Card · reporting suspected medicine side effects and product problems.
Editorial method: We compare identity assurance, quantity, sterility, storage, clinical oversight, adverse-event reporting and recourse separately. We never infer product quality from the molecule name alone.
If you suspect a problem
Questions people ask
Is a research-labelled semaglutide vial the same as Wegovy?
No. Wegovy is an authorised medicine with a defined formulation, presentation, manufacturing controls, batch release and product information. A research-labelled vial sold online is a separate product. Its label does not prove identity, strength, sterility, storage history or clinical equivalence.
Does a certificate of analysis make a grey-market vial safe?
No. A certificate can support only the attributes, sample and methods it actually covers. It may not be authentic or linked to the vial. Identity or purity results do not establish sterility, endotoxin, accurate quantity, stability, clinical suitability or safe use.
Are authorised GLP-1 medicines free from serious risks?
No. Authorised medicines have known side effects, contraindications and safety monitoring. The regulated route adds product assurance, clinical assessment and reporting systems. It does not remove risk, and it does not justify treating an unverified product as the same medicine.
Editorial experience
From our work: how we checked this page
For topical-map item C-030, Grey-market versus prescribed GLP-1 products was checked as a distinct editorial task, not treated as a generic peptide page. We reviewed 6 unique external sources and 10 internal destinations in the page, then checked that the opening answer, headings, source descriptions and linked next steps stayed within the same claim boundary. The count records links in the published page and is not a claim that every source carries equal evidential weight.
Eleni Kiromitis checked study design, biomedical evidence, evidence directness and laboratory context. Dr Stavroula Nikitopoulou checked clinical claims, adverse effects, contraindications, red flags and patient-facing safety wording. Each reviewer stayed within the remit published on the governance page. Yianni Kiromitis retained responsibility for source verification, editorial decisions and correction management.
We did not use patient experience, a personal treatment outcome, seller testimony or an assumed product identity to support this page. The publication did not independently test a vial for this review. Where a page refers to a laboratory result, that result applies only to the named sample, method and attribute. We kept uncertainty beside the conclusion, recorded which source supports each material claim, and checked that the visible review date matches the publication record. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.
Research reference checked and reviewed · 6 September 2026. Scientific review: Eleni Kiromitis. Clinical review: Dr Stavroula Nikitopoulou. The existing evidence verdict is unchanged; earlier sources retain their own check dates.